Frequency and clinical relevance of EGFR mutations and EML4–ALK translocations in octogenarians with non-small cell lung cancer

Amanda Tufman, Kathrin Kahnert, Thomas Duell, Diego Kauffmann-Guerrero, Katrin Milger, Christian Schneider, Julia Stump, Zulfiya Syunyaeva, Rudolf Maria Huber, Simone Reu
  • OncoTargets and Therapy, October 2017, Dove Medical Press
  • DOI: 10.2147/ott.s140472

EGFR mutations and EML4-ALK translocations in elderly patients with NSCLC

What is it about?

Very elderly patients with non-squamous NSCLC show high rates of driver alterations in EGFR and ALK

Why is it important?

Testing for EGFR and ALK alterations should not be restricted to younger patients, as they often are not suitable for cytotoxic therapy and may benefit from targeted treatments.

Perspectives

Professor Rudolf M. Huber
University of Munich and Thoracic Oncology Centre Munich

Biology of NSCLC in very elderly may be different.

open access logoRead Publication

http://dx.doi.org/10.2147/ott.s140472

The following have contributed to this page: Professor Rudolf M. Huber